Pneumocystis jirovecii: a review with a focus on prevention and treatment
R. Benson Weyant, Dima Kabbani, Karen Doucette, Cecilia Lau, Carlos Cervera
Abstract
: TMP-SMX has been first-line therapy for treating and preventing pneumocystis for decades. However, its adverse effects are not uncommon, particularly during treatment. Second-line therapies may be better tolerated, but often sacrifice efficacy. Echinocandins show some promise for new combination therapies; however, further studies are needed to define optimal antimicrobial therapy for PJP as well as the role of corticosteroids in those without HIV.
Topics & Concepts
MedicinePneumocystis jiroveciiIntensive care medicineDapsonePentamidinePneumoniaTrimethoprimAtovaquonePneumocystis pneumoniaClindamycinImmunologyInternal medicineAntibioticsMalariaPlasmodium falciparumMicrobiologyBiologyPneumocystis jirovecii pneumonia detection and treatmentPneumonia and Respiratory InfectionsTuberculosis Research and Epidemiology